In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Kura Oncology Inc (NASDAQ: KURA) closed the day trading at $5.69 down -2.23% from the previous closing price of $5.82. In other words, the price has decreased by -$2.23 from its previous closing price. On the day, 0.88 million shares were traded.
Ratios:
For a better understanding of KURA, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.75 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.46. For the most recent quarter (mrq), Quick Ratio is recorded 8.07 and its Current Ratio is at 8.07. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $27.
Stifel Downgraded its Buy to Hold on October 14, 2024, whereas the target price for the stock was revised from $26 to $19.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 19 ’25 when Bair Teresa Brophy sold 1,559 shares for $5.96 per share. The transaction valued at 9,292 led to the insider holds 107,948 shares of the business.
FORD KATHLEEN sold 1,558 shares of KURA for $9,777 on May 19 ’25. The Chief Operating Officer now owns 21,367 shares after completing the transaction at $6.28 per share. On May 19 ’25, another insider, FORD KATHLEEN, who serves as the Officer of the company, bought 1,558 shares for $5.96 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 7.25 while its Price-to-Book (P/B) ratio in mrq is 1.26.
Stock Price History:
Over the past 52 weeks, KURA has reached a high of $23.48, while it has fallen to a 52-week low of $5.41. The 50-Day Moving Average of the stock is -9.04%, while the 200-Day Moving Average is calculated to be -51.00%.
Shares Statistics:
A total of 86.57M shares are outstanding, with a floating share count of 82.28M. Insiders hold about 4.96% of the company’s shares, while institutions hold 89.32% stake in the company.
Earnings Estimates
The performance of Kura Oncology Inc (KURA) in the stock market is under the watchful eye of 10.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.64, with high estimates of $0.15 and low estimates of -$0.89.
Analysts are recommending an EPS of between -$0.14 and -$3.3 for the fiscal current year, implying an average EPS of -$2.06. EPS for the following year is -$1.95, with 10.0 analysts recommending between $0.88 and -$4.82.
Revenue Estimates
A total of 13 analysts have provided revenue estimates for KURA’s current fiscal year. The highest revenue estimate was $438.6M, while the lowest revenue estimate was $19.31M, resulting in an average revenue estimate of $161.42M. In the same quarter a year ago, actual revenue was $53.88MBased on 14 analysts’ estimates, the company’s revenue will be $204.01M in the next fiscal year. The high estimate is $451.2M and the low estimate is $20.05M.
